What is the purpose of conjugated monoclonal antibodies in cancer treatment?

The purpose of conjugated monoclonal antibodies in cancer treatment is to deliver targeted toxic substances directly to cancer cells. These antibodies are engineered to bind specifically to antigens that are overexpressed on the surface of cancer cells. By attaching a cytotoxic agent or drug to the antibody, it allows for the precise targeting of malignant cells while minimizing damage to surrounding healthy tissues.

This targeted approach enhances the efficacy of the treatment by ensuring that the toxic substance is concentrated where it is needed most, which can lead to improved treatment outcomes and reduced side effects compared to traditional chemotherapy methods that may affect a broader range of cells in the body. This strategy is particularly valuable in the complex landscape of cancer therapy, as it utilizes the body's immune system's ability to distinguish between normal and abnormal cells.